Search by Drug Name or NDC
NDC 45963-0734-54 Docetaxel 20 mg/mL Details
Docetaxel 20 mg/mL
Docetaxel is a INTRAVENOUS INJECTION, SOLUTION, CONCENTRATE in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by Actavis Pharma, Inc.. The primary component is DOCETAXEL.
MedlinePlus Drug Summary
Docetaxel injection is used alone or in combination with other medications to treat certain types of breast, lung, prostate, stomach, and head and neck cancers. Docetaxel injection is in a class of medications called taxanes. It works by stopping the growth and spread of cancer cells.
Related Packages: 45963-0734-54Last Updated: 11/30/2022
MedLinePlus Full Drug Details: Docetaxel Injection
Product Information
| NDC | 45963-0734 |
|---|---|
| Product ID | 45963-734_579fd04d-100e-4887-8d85-b95c3c3e28ea |
| Associated GPIs | 21500005001310 |
| GCN Sequence Number | 066751 |
| GCN Sequence Number Description | docetaxel VIAL 80 MG/4 ML INTRAVEN |
| HIC3 | V1F |
| HIC3 Description | ANTINEOPLASTICS,MISCELLANEOUS |
| GCN | 29066 |
| HICL Sequence Number | 010280 |
| HICL Sequence Number Description | DOCETAXEL |
| Brand/Generic | Generic |
| Proprietary Name | Docetaxel |
| Proprietary Name Suffix | n/a |
| Non-Proprietary Name | Docetaxel |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Dosage Form | INJECTION, SOLUTION, CONCENTRATE |
| Route | INTRAVENOUS |
| Active Ingredient Strength | 20 |
| Active Ingredient Units | mg/mL |
| Substance Name | DOCETAXEL |
| Labeler Name | Actavis Pharma, Inc. |
| Pharmaceutical Class | Microtubule Inhibition [PE], Microtubule Inhibitor [EPC] |
| DEA Schedule | n/a |
| Marketing Category | NDA |
| Application Number | NDA203551 |
| Listing Certified Through | 2024-12-31 |
Package
NDC 45963-0734-54 (45963073454)
| NDC Package Code | 45963-734-54 |
|---|---|
| Billing NDC | 45963073454 |
| Package | 1 VIAL, GLASS in 1 CARTON (45963-734-54) / 1 mL in 1 VIAL, GLASS |
| Marketing Start Date | 2014-09-01 |
| NDC Exclude Flag | N |
| Pricing Information | N/A |